Moteur de recherche d’entreprises européennes
Financement de l’UE (3 237 962 €) : Faire progresser la recherche à l’intersection entre le microbiote intestinal et la cachexie cancéreuse pour former les futurs leaders européens de la médecine du … Hor16/07/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Faire progresser la recherche à l’intersection entre le microbiote intestinal et la cachexie cancéreuse pour former les futurs leaders européens de la médecine du microbiote
Microbiota medicine is the new frontier in human health. The human gastrointestinal tract is home to trillions of microbes. Under normal conditions, these microbial communities drive physiological and homeostatic functions in the host; when altered, they can lead to severe disorders. With an increasingly recognized role in health and disease, the gut microbiota offers promising therapeutic and diagnostic potential to tackle various pathologies (incl. metabolic, neurological, and cardiovascular disorders). Its full clinical potential remains largely unrealized though, mostly due to the lack of critical mass capable of integrating the multiple scientific and translational dimensions of microbiota medicine. Grounded on a team of 180leading researchers and entrepreneurs from across 12 countries and dispersed disciplines (biological big data analytics, systems and synthetic biology, experimental and translational medicine), MiCCrobioTAckle will train 12 Doctoral Candidates (DCs) with the much-needed cross-disciplinary and -sectoral expertise to advance microbiota medicine. As course-setting disease, the DCs will focus on cancer cachexia (CC). CC is an excellent model to study the host-microbiota axis in the context of metabolic diseases and represents the paradigm of a devastating condition in urgent need of new and more efficient means of clinical management. Along MiCCrobioTAckle, the 12 high-calibre DCs will foster new discoveries with impact on CC, while driving scientific and technological progress in microbiota medicine in its broadest scope. By training the next generation of researchers with out-of-the-box thinking and an entrepreneurial mindset in microbiota medicine, MiCCrobioTAckle will safeguard the EU leadership in this vanguard and imperative biotech/pharma segment, while paving the way for the development of novel gut microbiota insights and tools to tackle multiple diseases with foreseeable impact on the well-being of billions of citizens worldwide.
https://cordis.europa.eu/project/id/101169068
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Abzu ApS, Nordhavn, Danemark.